Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSL | P07711 | 2/20 | 0.54 |
| ▸ | MMP2 | P08253 | 4/20 | 0.49 |
| ▸ | MMP9 | P14780 | 4/20 | 0.49 |
| ▸ | MMP7 | P09237 | 2/20 | 0.49 |
| ▸ | MMP1 | P03956 | 1/20 | 0.49 |
| ▸ | MMP3 | P08254 | 1/20 | 0.49 |
| ▸ | MMP14 | P50281 | 1/20 | 0.49 |
| ▸ | NR3C1 | P04150 | 4/20 | 0.47 |
| ▸ | NR3C2 | P08235 | 2/20 | 0.47 |
| ▸ | F2 | P00734 | 7/20 | 0.47 |
| ▸ | PGR | P06401 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 2/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3906292 | 0.83 | ADAM17 (0.48) | F2 | |
| SCHEMBL3914487 | 0.80 | CAPN1 (0.62) | MMP1F2SMN1; SMN2 | |
| SCHEMBL7377201 | 0.79 | CTSL (0.51) | CTSLMMP2MMP9MMP7MMP1 | |
| SCHEMBL7782244 | 0.77 | HDAC8 (0.49) | CTSLMMP2MMP9MMP7MMP1 | |
| SCHEMBL3909187 | 0.77 | CTSL (0.47) | CTSLMMP2MMP9MMP7MMP1 | |
| SCHEMBL3904383 | 0.77 | NR3C1 (0.63) | CTSLMMP2MMP9MMP1MMP14 | |
| SCHEMBL3906364 | 0.77 | CTSL (0.56) | CTSLMMP2MMP9NR3C1NR3C2 | |
| SCHEMBL7290418 | 0.76 | MMP9 (0.77) | MMP2MMP9MMP7MEN1KMT2A | |
| SCHEMBL7290422 | 0.76 | MMP9 (0.77) | MMP2MMP9MMP7MEN1KMT2A | |
| SCHEMBL4415259 | 0.75 | NR3C1 (0.64) | MMP2MMP9MMP7NR3C1NR3C2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7572833-B2 | Drug composition comprising dipeptidyl aldehyde derivative | SENJU PHARMACEUTICAL CO., LTD. (JP) | 2009-08-11 | — | — | US | disclosed |
| US-7052714-B1 | Ophthalmic adhesive preparations for percutaneous adsorption | SENJU PHARMACEUTICAL CO., LTD (JP) | 2006-05-30 | — | — | US | disclosed |
| US-20040048929-A1 | Drug composition comprising dipeptidyl aldehyde derivative | SENJU PHARMACEUTICAL CO., LTD. (JP) | 2004-03-11 | — | — | US | disclosed |
| EP-1334718-A1 | DRUG COMPOSITION COMPRISING DIPEPTYDYL ALDEHYDE DERIVATIVE | Senju Pharmaceutical Co., Ltd. (JP) | 2003-08-13 | — | — | EP | disclosed |
| EP-0927716-B1 | Angiogenesis inhibitor | SENJU PHARMA CO (JP) | 2003-05-07 | — | — | EP | disclosed |
| US-6551999-B1 | For therapy and prophylaxis of angiogenesis associated with wound healing, inflammation, growth of tumor and the like; angiogenesis as seen in diabetic retinopathy, prematurity retinopathy, retinal venous occlusion, metastasis of tumors | SENJU PHARMACEUTICAL CO., LTD. (JP) | 2003-04-22 | — | — | US | disclosed |
| EP-0771565-B1 | Angiogenesis inhibitor | SENJU PHARMA CO (JP) | 2003-01-02 | — | — | EP | disclosed |
| EP-1221315-A1 | OPHTHALMIC ADHESIVE PREPARATIONS FOR PERCUTANEOUS ABSORPTION | Senju Pharmaceutical Co., Ltd. (JP) | 2002-07-10 | — | — | EP | disclosed |
| US-6214800-B1 | ANGIOGENESIS INHIBITORS | SENJU PHARMACEUTICAL CO., LTD. (JP) | 2001-04-10 | — | — | US | disclosed |
| US-6057290-A | ADMINISTERING A CYSTEINE PROTEASE INHIBITOR TO A PATIENT FOR INHIBITING ANGIOGENESIS | SENJU PHARMACEUTICAL CO., LTD. (JP) | 2000-05-02 | — | — | US | disclosed |
| EP-0928786-A1 | Angiogenesis inhibitor | Senju Pharmaceutical Co., Ltd. (JP) | 1999-07-14 | — | — | EP | disclosed |
| EP-0927716-A1 | Angiogenesis inhibitor | Senju Pharmaceutical Co., Ltd. (JP) | 1999-07-07 | — | — | EP | disclosed |
| EP-0771565-A2 | Angiogenesis inhibitor | Senju Pharmaceutical Co., Ltd. (JP) | 1997-05-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040048929-A1 | Drug composition comprising dipeptidyl aldehyde derivative | DPP4, DPP3, DPP7 | CTSL 2253/4885MMP2 627/4885MMP9 589/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.